Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05445778 |
|---|---|
| Brief Title: | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) |
| First Submitted : | June 30, 2022 |
| First Submitted that Met QC Criteria : | June 30, 2022 |
| First Posted : | July 6, 2022 |
| Last Update Submitted that Met QC Criteria : | March 28, 2024 |
| Last Update Posted : | March 29, 2024 |